Vishal Deshmukh, PhD is a biopharmaceutical scientist and investor with rich expertise spanning early discovery through clinical development across multiple therapeutic areas. He is recognized for his leadership in advancing small-molecule and biologics programs in oncology and other serious diseases.
Vishal is a member of the investment team at Foresite Capital, focused on biotechnology investments. Prior to joining Foresite, he served as Director of Discovery Biology at Kinnate Biopharma, where he led early discovery and development efforts for small-molecule oncology therapeutics. Earlier in his career, Vishal was Director of Biology at Biosplice Therapeutics, managing programs across oncology, musculoskeletal, and dermatology indications and contributing to multiple IND submissions and a Phase 3 clinical study.
Before that, Vishal was a Visiting Scientist at the California Institute for Biomedical Research (Calibr) and the Genomics Institute of the Novartis Research Foundation (GNF), where he worked on small-molecule and biologics discovery and development. He earned his Ph.D. in Biology from The Scripps Research Institute, where he trained in the laboratory of Dr. Peter Schultz and was a California Institute for Regenerative Medicine (CIRM) graduate research fellow. He also holds an M.S. in Biotechnology from the University of California, Irvine, and a B.S. in Pharmaceutical Sciences from the Institute of Chemical Technology, Mumbai.